<DOC>
	<DOCNO>NCT01236378</DOCNO>
	<brief_summary>Sirolimus , 1 mg , white , triangular tablet ( RapamuneÂ® ) approve 03 April 2007 China prophylaxis organ rejection renal transplantation . A pharmacokinetic ( PK ) study conduct renal allograft recipient request State Food Drug Administration ( SFDA ) provide guidance clinical use . To minimize risk patient , study design collect blood PK sample renal allograft recipient currently sirolimus ( 1 mg tablet ) treatment without concomitant medication ( ) . PK sample collect patient characterize steady state PK sirolimus sirolimus maintenance therapy . This study involve change establish treatment regimen patient enroll study</brief_summary>
	<brief_title>Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Male female , 18 year age Body Mass Index ( BMI ) 18.0 25.0 kg/m2 , inclusive ; Subjects must receive primary secondary renal allograft least 2 month prior Screening ; Subjects must currently take Rapamune tablet prophylaxis renal rejection . The dosages medication must stable least 2 week prior screen continue change completion last PK sample collection . Acute rejection vascular rejection episode 4 week prior Screening ; patient dependent dialysis ; inadequate renal function ( opinion investigator ) ; Recipients multiple organ transplant ( i.e. , prior concurrent transplantation organs renal transplant ) ; Current use strong inducer inhibitor CYP3A4 within 2 week prior collection first PK sample collection final PK sample ; Any clinically significant medical psychiatric condition laboratory abnormality , judgment investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Organ Transplants</keyword>
	<keyword>Anti-Rejection Therapy</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>